Goodnight whether good morning – when to take statins? Review article
Article Sidebar
Published:
Jun 30, 2017
Keywords:
statins, pharmacokinetics
Main Article Content
Abstract
Statins are crucial for pharmacotherapy of dyslipidemia for decades. Regardless commune long-term use of drugs in this group, numbers of clinical studies showing good tolerance of clinical benefits of statins, there are still some myth as far as those drugs are concerned. Guideline to take statins only in the evening is one of those. As usually in every myth there is a grain of truth. The knowledge of pharmacokinetics of statins lets us make a clear statement – the principle “only in the evening” dose not refer to all statins.
Article Details
How to Cite
Wełnicki , M., & Mamcarz , A. (2017). Goodnight whether good morning – when to take statins?. Medycyna Faktow (J EBM), 10(2(35), 99-102. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2149
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Preiss B.: Regulation of HMG-CoA Reductase. Elsevier, Amsterdam 1985.
2. Martonosi A.: The Enzymes of Biological Membranes: Volume 2. Biosynthesis of Cell Components. Springer Science & Business Media, 2012.
3. Botham K.M., Mayes P.A.: Synteza, transport i wydalanie cholesterolu. W: Murray R.K., Granner D.K., Rodwell V.W. (red.): Biochemia Harpera. Wydawnictwo Lekarskie PZWL, wyd. 6 uaktualnione, Warszawa 2010.
4. Mahley R.W., Bersot T.P.: Leki stosowane w hipercholesterolemii oraz w dyslipidemii. W: Brunton L.L., Lazo J.S., Parker K.L. (red.): Farmakologia Goodmana & Gilmana. T. 1. Wyd. 1. Wydawnictwo Czelej Sp. z o.o., Lublin 2007: 991.
5. Mckenney J.M.: Pharmacologic characteristics of statins. Clin. Cardiol. 2003; 26(supl. III): III32-III38.
6. Schachter M.: Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. 2004; 19: 117-125.
7. Cilia D., Gibson D., Whitfield R., Sedman A.: Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J. Clin. Pharmacol. 1996; 36: 604-609.
2. Martonosi A.: The Enzymes of Biological Membranes: Volume 2. Biosynthesis of Cell Components. Springer Science & Business Media, 2012.
3. Botham K.M., Mayes P.A.: Synteza, transport i wydalanie cholesterolu. W: Murray R.K., Granner D.K., Rodwell V.W. (red.): Biochemia Harpera. Wydawnictwo Lekarskie PZWL, wyd. 6 uaktualnione, Warszawa 2010.
4. Mahley R.W., Bersot T.P.: Leki stosowane w hipercholesterolemii oraz w dyslipidemii. W: Brunton L.L., Lazo J.S., Parker K.L. (red.): Farmakologia Goodmana & Gilmana. T. 1. Wyd. 1. Wydawnictwo Czelej Sp. z o.o., Lublin 2007: 991.
5. Mckenney J.M.: Pharmacologic characteristics of statins. Clin. Cardiol. 2003; 26(supl. III): III32-III38.
6. Schachter M.: Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. 2004; 19: 117-125.
7. Cilia D., Gibson D., Whitfield R., Sedman A.: Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J. Clin. Pharmacol. 1996; 36: 604-609.